A New Chapter in ADHD Treatment? Alkermes ALKS 7290 Shows Promise in Early Trial
A New Chapter in ADHD Treatment? Alkermes ALKS 7290 Shows Promise in Early Trial
Imagine struggling to focus on a simple task, your thoughts racing in a dozen directions at once. For adults with ADHD, this isnt just a momentary distraction—its a daily reality. Current treatments help many, but they dont work for everyone, and side effects can be a dealbreaker. Thats why the latest news from Alkermes is turning heads.
The company just announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290, an investigational medication for adults with ADHD. The data, released in an SEC filing on September 21, 2026, suggests the drug could offer meaningful symptom relief with a tolerability profile that has researchers optimistic.
What the Numbers Say
In the trial, participants taking ALKS 7290 showed dose-dependent improvements on the Adult ADHD Investigator Symptom Rating Scale (AISRS). At day 14, those on the 20 mg dose saw an average reduction of 14 points, while the 50 mg group dropped 19 points. To put that in perspective, a 14-point drop is considered clinically meaningful—its not just a statistical blip, but something patients might actually feel in their daily lives.
The Clinical Global Impression-Severity (CGI-S) scale told a similar story. Median scores improved by 1.0 point in the 20 mg group and 2.0 points in the 50 mg group, shifting participants from “moderately ill” toward “mildly ill” by day 14. Thats a quick turnaround for a condition that often requires weeks of dose titration with existing therapies.
Safety First
Perhaps the most encouraging news is the safety profile. ALKS 7290 was generally well tolerated. There were no serious treatment-emergent adverse events (TEAEs) and no discontinuations among treated participants. For a field where stimulant medications often bring side effects like insomnia, appetite loss, or jitteriness, a clean safety signal in early trials is noteworthy.
The study also used EEG and cognitive tests to peek under the hood. Results showed central activity—meaning the drug is doing something in the brain—and benefits across processing speed, working memory, and attention. These are exactly the domains where ADHD hits hardest, so seeing improvements across the board is a promising sign.
Whats Next?
Alkermes isnt wasting any time. A Phase 2 trial in adults with ADHD is already enrolling, with about 312 participants planned. The first participant was dosed in September 2026, and data is expected in 2027. Thats a relatively brisk timeline, suggesting the company sees real potential here.
Of course, Phase 1b is just the beginning. Many drugs that look good early fail in larger trials. But the combination of symptom reduction, functional improvement, and tolerability gives ALKS 7290 a fighting chance.
Why It Matters
ADHD in adults is often overlooked or misdiagnosed. Many people struggle for years before finding a treatment that works. The current landscape includes stimulants and non-stimulants, but neither is perfect. A new option with a different mechanism could be a game-changer—especially for those who dont respond to or cant tolerate existing medications.
Alkermes has a history in CNS disorders, and this trial adds to their pipeline. Investors reacted cautiously—the stock dipped slightly—but early-stage data often comes with volatility. The real test will be Phase 2.
For now, the takeaway is simple: a new ADHD treatment candidate just cleared an important hurdle. Its not a cure, and its not available yet, but its a step forward. If you or someone you know struggles with ADHD, this is a development worth watching.
What questions would you ask about a new ADHD medication? The answers may shape the next generation of treatments.
Autorius
Mike Brown
Mike Brown – One of those authors who helps readers not get lost in today's news flow. He dives into political affairs as well as world events, social trends, and everyday stories that matter to everyone. The main focus of his work is fact-checking, clear language, and the ability to lay out the key points so that the reader gets a comprehensive and reliable picture of the topic in just a few minutes.
Related Articles
Comments
No comments yet.